It indicates that while IHH may signal through SMO to activate GLI1, it is the non-canonical activation of GLI1 that dominates in CS cells, and this proposed novel regulatory mechanism of MVP/mTOR/GLI1 axis may possibly explain the failure of recent clinical trials using SMO antagonists in patients with advanced CS. The gene discussed is MVP; the disease is Cowden syndrome 1.